BioTuesdays

Category - Markets

Markets

WB starts Actinium Pharma at OP

William Blair launched coverage of Actinium Pharmaceuticals (NASDAQ:ATNM) with an “outperform” rating based on its view that the company’s potent and specific radiopharmaceuticals for improving treatment options of...

August 8, 2019
AxoGen
Markets

WB cuts AxoGen to MP from OP

William Blair downgraded AxoGen (NASDAQ:AXGN) to “market perform” from “outperform” after the company reduced revenue guidance for 2019. The stock closed at $17.58 on Aug. 6, near the low end of its 52-week range of $14...

August 7, 2019
Markets

BTIG ups Tactile Systems to buy with $62 PT

BTIG upgraded Tactile Systems Technology (NASDAQ:TCMD) to “buy” from “neutral” with a price target of $62. The stock closed at $49.30 on Aug. 6. Tactile Medical is a leader in developing and marketing at-home therapy...

August 7, 2019
Alphatec Spine Logo
Markets

Piper starts Alphatec at OW; PT $7

Piper Jaffray launched coverage of Alphatec Holdings (NASDAQ:ATEC) with an “overweight” rating and $7 price target. The stock closed at $4.80 on Aug. 2. Alphatec is a pure play spine provider that is introducing a...

August 5, 2019
Markets

HCW starts MediWound at buy; PT $5.50

H.C. Wainwright initiated coverage of MediWound (NASDAQ:MDWD) with a “buy” rating and price target of $5.50. The stock closed at $2.58 on Aug. 2. MediWound is developing proteolytic enzyme-based eschar debridement...

August 5, 2019
Markets

Piper cuts Intersect ENT to neutral; PT to $17 from $30

Piper Jaffray downgraded Intersect ENT (NASDAQ:XENT) to “neutral” from “overweight” and slashed its price target to $17 from $30 after the company reported second quarter results and lowered its revenue guidance to flat...

August 2, 2019
T2 Biosystems Logo
Markets

AGP cuts T2 Biosystems to neutral; PT 40 cents

Alliance Global Partners downgraded T2 Biosystems (NASDAQ:TTOO) to “neutral” from “buy” with a price target of 40 cents after the company reported second quarter results. The stock closed at 59 cents on Aug. 1. The...

August 2, 2019
Cellectar Biosciences Logo
Markets

Brookline starts Cellectar Biosciences at buy; PT $6

Brookline Capital Markets launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and price target of $6. The stock closed at $2.14 on July 29. Cellectar has a unique cancer target delivery platform...

July 30, 2019